Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11035
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCebon, Jonathan Sen
dc.date.accessioned2015-05-16T00:36:50Z
dc.date.available2015-05-16T00:36:50Z
dc.date.issued2010-03-01en
dc.identifier.citationAsia-pacific Journal of Clinical Oncology; 6 Suppl 1(): S9-15en
dc.identifier.govdoc20482531en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/11035en
dc.description.abstractAbstract The discovery that the immune system can distinguish molecular targets on cancer cells has led to efforts to develop cancer immunotherapeutics that can improve the recognition and effective elimination of tumor cells. Several types of tumor antigens are recognized by T lymphocytes, which are classified according to patterns of gene expression or protein distribution. Of particular interest is the group of molecules known as cancer-germline or cancer-testis antigens. As the relationship between the immune system and cancer has become clearer, so too have the challenges in designing effective cancer immunotherapeutics: (i) antigens need to be specifically selected based on ideal characteristics, such as tissue distribution that is restricted to tumors; (ii) selected antigens need to be combined with adjuvant agents that enhance their immunogenicity and yield robust responses; (iii) vaccination should be timed to pre-empt the development of regulatory suppressive immune mechanisms; and (iv) if suppressive regulatory mechanisms do arise, specific antagonists may be needed to enhance pro-immune outcomes. These challenges are shaping current and future research in this area.en
dc.language.isoenen
dc.subject.otherAnimalsen
dc.subject.otherAntigens, Neoplasm.immunologyen
dc.subject.otherCancer Vaccines.immunology.therapeutic useen
dc.subject.otherClinical Trials as Topicen
dc.subject.otherHumansen
dc.subject.otherNeoplasms.immunology.therapyen
dc.subject.otherTumor Escape.immunologyen
dc.titleCancer vaccines: Where are we going?en
dc.typeJournal Articleen
dc.identifier.journaltitleAsia-Pacific journal of clinical oncologyen
dc.identifier.affiliationjonathan.cebon@ludwig.edu.auen
dc.identifier.affiliationAustin Ludwig Oncology Unit, Ludwig Institute, Melbourne, Victoria, Australiaen
dc.identifier.doi10.1111/j.1743-7563.2010.01270.xen
dc.description.pagesS9-15en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/20482531en
dc.type.austinJournal Articleen
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

8
checked on Feb 6, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.